The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).
Irfan Firdaus
No relevant relationships to disclose
Kent C. Shih
No relevant relationships to disclose
Ahmed Zakari
No relevant relationships to disclose
Evan Z. Lang
No relevant relationships to disclose
Michael McCleod
No relevant relationships to disclose
Kathryn B. Alguire
No relevant relationships to disclose
Nancy Walker Peacock
No relevant relationships to disclose
Douglas B. Flora
No relevant relationships to disclose
Peter Ruehlman
No relevant relationships to disclose
Chris Earwood
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose